Trial Profile
A Phase2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, on Allergen-Induced Interleukin-9 Levels in Bronchoalveolar Lavage Fluid in Adults With Atopic Asthma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Enokizumab (Primary)
- Indications Allergic asthma; Asthma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors MedImmune
- 18 Feb 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 25 Aug 2008 Status changed from recruiting to suspended (clinical hold), as reported by ClinicalTrials.gov
- 25 Oct 2007 Preliminary tolerability data has been reported.